Development and Validation of RP- HPLC Method for Simultaneous Determination of Niacin (Extended Release) and Lovastatin in Oral Solid Dosage Form | Chapter 14 | Novel Aspects on Pharmaceutical Research Vol. 1

The present study proposed to develop a novel RP-HPLC Method for the guess of Niacin and Lovastatin in Bulk and spoken solid dosage form. For the concurrent estimation of lovastatin and niacin in a linked dosage form, a simple, accurate, and fast HPLC method has existed created and validated. Chromatographic break-up of the two drugs was acted on a Purospher BDS C8 column (150 mm× 4.6 mm id, 5µm piece size). The travelling phase secondhand was a mixture of 0.1% v/v triethylamine (pH 5.0), holding 20 mM of Ammonium acetate buffer: methanol (30:70% v/v).Detection was acted at 237nm and sharp peaks were obtained for niacin and Lovastatin at memory times of 3.2±0.01 brief time period and.6.4±0.01 min individually. The calibration curve was uninterrupted in the concentration range 100-700µg/ml for niacin 3-18µg/ml for Lovastatin; the correlation coefficients were 0.9991 and 0.9992, individually. According to the International Conference on Harmonization (ICH) Q2 (R1) guidelines, the optimised procedure performed well in agreements of specificity, extent of object, detection and quantitation limits, accuracy, and accuracy. It has been proved that this assay can be used to frequently quantify lovastatin and niacin in medicine dosage form. High portion recovery of drug shows the arrangement is free from inference of excipients present in the expression. The proposed form was found appropriate for simultaneous reasoning of NI and LT can be secondhand for routine quality control of their most drug mixture and their combined portion of drug or other consumable form.

Author(s) Details:

G. S. Devika,
Department of Pharmaceutical Analysis, Cherraans College of Pharmacy, Siruvani Main Road, Coimbatore, Tamil nadu, India.

R. Ramesh Petchi,
Department of Pharmacology, Cherraans College of Pharmacy, Siruvani Main Road, Coimbatore, Tamil nadu, India.

M. Sudhakar,
Department of Pharmaceutical Chemistry, Malla Reddy College of Pharmacy, Maissamaguda, Dullapally, Secunderabad -14, Andrapradesh, India.

J. Venkateshwara Rao,
Department of Pharmaceutical Chemistry, Sultan Ul Uloom College of Pharmacy, Road No 3, Banjara Hills, Secunderabad- 500034, Andra Pradesh, India.


Please see the link here: https://stm.bookpi.org/NAPR-V1/article/view/10429

Encapsulation of Anti-dyslipidemic Drug as a Controlled Release Tablet Using Proanthocyanidin Polymer | Book Publisher International

 Many people today are at high risk of coronary heart disease, and few drugs are available to assist them achieve their lipid goals. Niacin is one of the most promising drugs for dyslipidemia, with impressive lipid profile improvements. Nicotinic acid (Niacin) is the most effective medication for changing lipid diseases such as raised non-HDL cholesterol, elevated lipoproteins, elevated triglycerides, and lowering HDL cholesterol, and is thus useful in reducing residual cardiovascular risk and dyslipidemia. We will discuss extended release dosage forms, factors that cause dyslipidemia and its symptoms, nicotinic acid mechanism, applications, and how it aids in the treatment of dyslipidemia, proanthocyanidin polymer, and the development of nicotinic acid controlled release tablet with proanthocyanidin polymer using the encapsulation technique in this book. The goal of this method of creating nicotinic acid tablets is to establish a constant drug level in plasma with fewer oscillations by releasing the medication slowly over time. The encapsulation efficiency was 99.73 percent and the drug content was 99.52 percent. The medicine was released at a rate of 97.2 percent for up to 12 hours, and at a rate of 97.74 percent for 11 hours. The medication was released in a zero-order sequence. The findings suggested that NA controlled-release tablets created using encapsulation are more effective than traditional dosage forms and have improved patient compliance. This book experiments and studies the efficacy of nicotinic acid in decreasing cholesterol levels and treating dyslipidemia, as well as the efficacy of nicotinic acid as a controlled release.

Author(s) Detalis

Ravi Manne
Environmental & Industrial Hygiene Services, Chemtex, Port Arthur, Texas, USA.

Agilandeswari Devarajan
Research & Development, Synapsesai India Private Limited, Indore, Uttar Pradesh, India.

View Book:- https://stm.bookpi.org/EADCRTUPP/article/view/1890